Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARWRNASDAQ:INSMNASDAQ:MRTXNYSE:OGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$15.32-1.9%$14.68$9.57▼$30.41$2.12B0.961.54 million shs2.78 million shsINSMInsmed$102.68+3.2%$74.81$60.40▼$102.81$19.48B0.82.16 million shs4.67 million shsMRTXMirati Therapeutics$58.70$58.82$27.30▼$64.41$4.12B0.772.76 million shsN/AOGNOrganon & Co.$9.77-1.2%$9.88$8.01▼$23.10$2.53B0.583.46 million shs4.77 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals0.00%-2.67%-0.45%+3.51%-35.02%INSMInsmed0.00%+4.00%+55.20%+28.48%+56.57%MRTXMirati Therapeutics0.00%0.00%0.00%0.00%0.00%OGNOrganon & Co.0.00%-2.59%+12.16%-36.30%-52.01%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARWRArrowhead Pharmaceuticals3.5222 of 5 stars3.41.00.03.42.42.50.0INSMInsmed3.4169 of 5 stars2.51.00.04.33.21.70.6MRTXMirati TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOGNOrganon & Co.4.6869 of 5 stars3.32.01.73.71.83.32.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARWRArrowhead Pharmaceuticals 2.75Moderate Buy$43.71185.34% UpsideINSMInsmed 3.00Buy$106.804.01% UpsideMRTXMirati Therapeutics 0.00N/AN/AN/AOGNOrganon & Co. 2.50Moderate Buy$18.0084.33% UpsideCurrent Analyst Ratings BreakdownLatest OGN, MRTX, INSM, and ARWR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025INSMInsmedThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$100.00 ➝ $112.006/11/2025INSMInsmedMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$96.00 ➝ $110.006/11/2025INSMInsmedRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$99.00 ➝ $106.006/11/2025INSMInsmedMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$90.00 ➝ $102.006/11/2025INSMInsmedWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$107.00 ➝ $119.006/11/2025INSMInsmedBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$94.00 ➝ $109.006/11/2025INSMInsmedHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$90.00 ➝ $120.006/10/2025INSMInsmedJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/10/2025INSMInsmedCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy6/10/2025INSMInsmedLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$100.00 ➝ $115.005/22/2025OGNOrganon & Co.BNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARWRArrowhead Pharmaceuticals$3.55M595.97N/AN/A$1.54 per share9.95INSMInsmed$363.71M53.56N/AN/A$1.60 per share64.18MRTXMirati Therapeutics$12.44M331.01N/AN/A$17.31 per share3.39OGNOrganon & Co.$6.40B0.40$4.93 per share1.98$1.83 per share5.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARWRArrowhead Pharmaceuticals-$599.49M-$1.40N/AN/A18.02N/A-45.33%-12.49%8/6/2025 (Estimated)INSMInsmed-$913.77M-$5.95N/AN/AN/A-265.93%-446.98%-52.70%8/6/2025 (Estimated)MRTXMirati Therapeutics-$740.87M-$12.22N/AN/AN/A-1,900.65%-82.15%-67.82%N/AOGNOrganon & Co.$864M$2.883.392.611.0211.92%227.43%7.34%8/5/2025 (Estimated)Latest OGN, MRTX, INSM, and ARWR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q2 2025ARWRArrowhead Pharmaceuticals-$0.06$2.75+$2.81$2.75$116.27 million$542.71 million5/8/2025Q1 2025INSMInsmed-$1.36-$1.42-$0.06-$1.42$91.63 million$92.82 million5/1/2025Q1 2025OGNOrganon & Co.$0.89$1.02+$0.13$0.33$1.53 billion$1.51 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/AMRTXMirati TherapeuticsN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.82%N/A2.78%N/ALatest OGN, MRTX, INSM, and ARWR DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025OGNOrganon & Co.quarterly$0.020.8%5/12/20255/12/20256/12/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARWRArrowhead Pharmaceuticals0.315.155.15INSMInsmed11.385.865.44MRTXMirati TherapeuticsN/A7.547.40OGNOrganon & Co.16.491.671.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARWRArrowhead Pharmaceuticals62.61%INSMInsmedN/AMRTXMirati TherapeuticsN/AOGNOrganon & Co.77.43%Insider OwnershipCompanyInsider OwnershipARWRArrowhead Pharmaceuticals4.30%INSMInsmed3.00%MRTXMirati Therapeutics3.26%OGNOrganon & Co.1.96%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARWRArrowhead Pharmaceuticals400138.10 million132.16 millionOptionableINSMInsmed1,271189.71 million184.02 millionOptionableMRTXMirati Therapeutics58770.15 million67.86 millionOptionableOGNOrganon & Co.4,000259.96 million254.86 millionNot OptionableOGN, MRTX, INSM, and ARWR HeadlinesRecent News About These CompaniesOGN Investors Have Opportunity to Lead Organon & Co. Securities Fraud LawsuitJune 21 at 5:49 PM | gurufocus.comORGANON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGNJune 20 at 10:50 PM | prnewswire.comOGN Investors Have Opportunity to Lead Organon & Co. Securities Fraud LawsuitJune 20 at 5:18 PM | prnewswire.comOGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJune 20 at 4:00 PM | globenewswire.comDeadline Alert: Organon & Co. (OGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud LawsuitJune 20 at 12:35 PM | globenewswire.comFaruqi & Faruqi Reminds Organon Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2025 - OGNJune 20 at 11:22 AM | prnewswire.comOGN COURT REMINDER: Organon & Co. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 22 Court Deadline (NYSE:OGN)June 20 at 9:06 AM | globenewswire.comLevi & Korsinsky Reminds Organon Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2025 - OGNJune 20 at 9:00 AM | prnewswire.comCantor Fitzgerald Investment Advisors L.P. Decreases Position in Organon & Co. (NYSE:OGN)June 20 at 7:19 AM | marketbeat.comSG Americas Securities LLC Invests $829,000 in Organon & Co. (NYSE:OGN)June 20 at 3:28 AM | marketbeat.comOrganon & Co. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2025 to Discuss Your Rights – OGNJune 19 at 4:00 PM | globenewswire.comInvestors who lost money on Organon & Co.(OGN) should contact The Gross Law Firm about pending Class Action - OGNJune 19 at 9:00 AM | prnewswire.comORGANON & CO. (NYSE: OGN) INVESTOR ALERT: Investors With Large Losses in Organon & Co. Should Contact Bernstein Liebhard LLP To Discuss Their RightsJune 19 at 8:15 AM | globenewswire.comOrganon & Co. (NYSE:OGN) Given Average Rating of "Moderate Buy" by BrokeragesJune 19 at 4:26 AM | marketbeat.comORGANON SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGNJune 18, 2025 | investing.comORGANON SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGNJune 18, 2025 | globenewswire.comROSEN, A RANKED AND LEADING FIRM, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OGNJune 18, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon & Co.of Class Action Lawsuit and Upcoming Deadlines - OGNJune 18, 2025 | globenewswire.comJuly 22, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against OGNJune 18, 2025 | globenewswire.comOGN NOTICE: Did Organon & Co. Mislead Investors? Contact BFA Law by July 22 Court Deadline if You Suffered Losses (NYSE:OGN)June 18, 2025 | globenewswire.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of OrganonJune 18, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsRussell Rebalance: 3 Stocks Ready to Move HigherBy Chris Markoch | June 20, 2025View Russell Rebalance: 3 Stocks Ready to Move HigherOGN, MRTX, INSM, and ARWR Company DescriptionsArrowhead Pharmaceuticals NASDAQ:ARWR$15.32 -0.30 (-1.92%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$15.35 +0.03 (+0.20%) As of 06/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Insmed NASDAQ:INSM$102.68 +3.22 (+3.24%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$102.69 +0.01 (+0.01%) As of 06/20/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Mirati Therapeutics NASDAQ:MRTXMirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.Organon & Co. NYSE:OGN$9.76 -0.12 (-1.16%) Closing price 06/20/2025 03:59 PM EasternExtended Trading$9.76 -0.01 (-0.10%) As of 06/20/2025 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
